SCHEMBL5100241

SCHEMBL5100241

CC(=O)c1sc(Cl)cc1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.40
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
DAO P14920 3/20 0.39
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
DHODH Q02127 2/20 0.36
KMT2A Q03164 3/20 0.36
HPGD P15428 3/20 0.36
GSK3B P49841 1/20 0.35
CA5A P35218 1/20 0.34
RXFP1 Q9HBX9 2/20 0.34
KDM4E B2RXH2 2/20 0.34
LMNA P02545 1/20 0.34
PKM P14618 1/20 0.34
MEN1 O00255 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.33
CYP3A4 P08684 1/20 0.33
USP7 Q93009 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25694555 0.80 F10 (0.46) MAPTALDH1A1POLBDAORAB9A
SCHEMBL10861484 0.80 MAPT (0.40) MAPTALDH1A1POLBDAORAB9A
SCHEMBL788357 0.79 DAO (0.50) ALDH1A1DAOSMN1; SMN2HPGDGSK3B
SCHEMBL13277701 0.78 GSK3B (0.41) MAPTALDH1A1POLBDAORAB9A
SCHEMBL9059332 0.76 DAO (0.38) DAOGSK3B
SCHEMBL26241185 0.75 DHODH (0.36) MAPTALDH1A1POLBRAB9ANPC1
SCHEMBL542159 0.68 DAO (0.65) MAPTPOLBDAORAB9ANPC1
SCHEMBL23151886 0.67 MAPT (0.47) MAPTALDH1A1POLBDAORAB9A
SCHEMBL3425861 0.67 DAO (0.48) MAPTALDH1A1POLBDAORAB9A
SCHEMBL3055848 0.67 DAO (0.39) MAPTALDH1A1DAORAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7425557-B2 Inhibitors of glycogen synthase kinase 3 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2008-09-16 US disclosed
US-7045519-B2 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-05-16 US disclosed
US-7037918-B2 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-05-02 US disclosed
US-20060089369-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION (US) 2006-04-27 US disclosed
EP-1087963-B1 INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 CHIRON CORP (US) 2004-08-25 EP disclosed
US-20030130289-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2003-07-10 US disclosed
US-6489344-B1 FOR TREATMENT DIABETES IN A HUMAN OR ANIMAL SUBJECT CHIRON CORPORATION 2002-12-03 US disclosed
US-20020156087-A1 Inhibitors of glycogen synthase kinase 3 CHIRON CORPORATION 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130289-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB MAPT 134/4885ALDH1A1 3522/4885POLB 624/4885
US-20060089369-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB MAPT 146/4885ALDH1A1 3532/4885POLB 692/4885
US-20020156087-A1 Inhibitors of glycogen synthase kinase 3 GSK3B, GSK3A, PYGB MAPT 146/4885ALDH1A1 3532/4885POLB 692/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.